Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126 Turin, Italy.
Maria Pia Hospital, 10126 Turin, Italy.
Cells. 2020 Feb 7;9(2):386. doi: 10.3390/cells9020386.
Liver diseases represent a major global health issue, and currently, liver transplantation is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain major obstacles. Hence, much hope has turned towards cell-based therapy. Hepatocyte-like cells obtained from embryonic stem cells or adult stem cells bearing multipotent or pluripotent characteristics, as well as cell-based systems, such as organoids, bio-artificial liver devices, bioscaffolds and organ printing are indeed promising. New approaches based on extracellular vesicles are also being investigated as cell substitutes. Extracellular vesicles, through the transfer of bioactive molecules, can modulate liver regeneration and restore hepatic function. This review provides an update on the current state-of-art cell-based and cell-free strategies as alternatives to liver transplantation for patients with end-stage liver diseases.
肝脏疾病是一个全球性的主要健康问题,目前,肝移植是降低终末期肝病患者死亡率的唯一可行方法。然而,供体器官的缺乏和需要再次移植的复发风险仍然是主要障碍。因此,人们将很大的希望寄托在基于细胞的治疗上。从胚胎干细胞或具有多能性或多能性特征的成体干细胞中获得的肝样细胞,以及基于细胞的系统,如类器官、生物人工肝设备、生物支架和器官打印,确实很有前途。基于细胞外囊泡的新方法也被作为细胞替代物进行研究。细胞外囊泡通过传递生物活性分子,可以调节肝脏再生并恢复肝功能。本文综述了目前基于细胞和无细胞的策略,作为肝移植的替代方法,用于治疗终末期肝病患者。